Abstract: The invention relates to a method for producing a drug delivery device, which has a body comprising a siloxane-based elastomer and at least one active agent. The method comprises applying adhesive material, which comprises non-cured siloxane based elastomer, into a contact with the body and curing the said adhesive material by subjecting it to radiation energy from a laser source. The invention relates also to a drug delivery device manufactured according to the method.

Abstract: A nasal spray or therapy solution is provided having organic glycerin; an organic preservative system containing glycerin, citrus reticulata fruit extract, citrus aurantium amara fruit extract, citrus aurantium sinensis peel extract, ascorbic acid, citric acid, lactic acid, water; sodium chloride; water; whereby said nasal spray exhibits inhibited bacteriological growth in vitro for up to 36 months.

Abstract: The present application relates to a nasal dosage form of dihydroergotamine, wherein said dosage form requires less than about 15 minutes for administration and requires less than four sprays to administer effective dose of dihydroergotamine for treating migraine in human subjects.

Abstract: Compositions, kits, and methods for treating for treating dry eyes in mammal, particularly humans, are described. Such compositions include a pharmaceutically or veterinarily acceptable ocular carrier and a therapeutically effective amount of one or more immune regulatory agents, for example, stimulators and activators of regulatory B or T cells, type 2 immunity-associated immune cells, including group 2 innate lymphoid cells, type 2 CD4+ T helper cells, and alternative activation of macrophages (AAMacs, M2).

Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Abstract: An oral preparation for treating cell proliferation diseases. The oral preparation comprises hydroxylpropoxyl-?-cyclodextrin and an active component. The active component is KX2-361 or a medicinal salt thereof, and KX2-361 is represented by formula 1. By mixing hydroxylpropoxyl-ydcyclodextrin with KX2-361 or the medicinal salt thereof, an inclusion complex is formed, the solubility of the poorly-soluble drug KX2-361 is greatly improved, and accordingly the drug is prepared into an oral preparation. The oral preparation has good stability, high safety, good absorbability, high bioavailability and economical cost.

Abstract: A self-film-forming composition in powder form, a reconstituted formula and a kit for oral use are provided, which allow an adequate colonization of the probiotic in the oral cavities together with a sufficient residence time to allow beneficial effects against the pathogens related with oral conditions. Thus, the items provided are useful for the prevention and/or treatment of a condition related to alterations of the oral microbiota, and specifically for peri-implantitis. The self-film-forming composition in powder form comprises at least a gelifier agent and/or at least a bioadhesive agent, and at least one lactic acid bacteria strain.

Abstract: The present invention relates to an animal feed bolus having two or more sections, wherein each section has a different composition. The different sections of the bolus are formulated to have different release times and/or to provide compositions with different nutritional purposes. Also described herein are methods for manufacturing such boluses, and methods for feeding an animal using such boluses.

Abstract: A gel comprising nano-sized particles of metallic silver (Ag), a polymer comprising carboxylate groups, carboxylate molecules comprising at least one group capable of binding to Ag, and metal ions, where the gel is useful as a topically applied antimicrobial agent.

Abstract: The purpose of the present invention is to provide a nanoparticle dispersion liquid of an ?-galactosylceramide-related compound that can be administered in the form of a stable dispersion liquid using water as a solvent. According to the present invention, it is possible to obtain a nanoparticle dispersion liquid, which is not in the form of a liposome dispersion liquid obtained by using a phospholipid or the like, and also to control the size of nanoparticles.

Abstract: The present invention relates to methods for treating and preventing acne or P. acnes infection in a subject comprising topically administering to the subject in need thereof an anti-acne nanoemulsion composition, comprising CPC or BKC as a cationic agent.

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Abstract: The present invention provides particulate delivery systems comprising plurality of particles comprising fenugreek gum and at least one pharmaceutically acceptable excipient. The particulate delivery systems of the present invention are used for the delivery of therapeutic, immunologic or diagnostic agents, and the like.

Abstract: Methods and formulations for a simplified, single-injection method to induce and control the synchronous growth (superstimulation), and ovulation (superovulation) of multiple ovarian follicles in bovine, ovine, caprine, camelid and other female animals enabling the subsequent collection of (a) multiple oocytes when conducting in-vitro fertilization, or (b) multiple embryos when conducting multiple ovulation embryo transfer.

Abstract: An object of the present invention is to provide a compression-molded preparation which has an excellent disintegration property and can be easily produced despite the use of granules coated with a polymer coating film having a function such as masking of an unpleasant taste. A compression-molded preparation achieving the above object is characterized by including granules obtained by coating a polymer-coated, granulated substance, in which a granulated substance containing a drug is coated with a polymer coating film, with one kind or two or more kinds of additives selected from the group consisting of a metal stearate, stearic acid, a sucrose fatty acid ester, talc, and silicic acid.

Abstract: The present disclosure relates to oral, abuse deterrent, edible soft chewable dosage forms for delivery of drugs that are susceptible to abuse to a human or animal subject. The dosage forms are provided as chewable tablets manufactured using a compression (tablet) press. The edible soft chew dosage forms can be administered to subjects that are unable to swallow conventional tablets or capsules whole. One or more abuse deterrent measures in the dosage forms prevent the conversion of the dosage form into a residue or extract suitable for non-oral administration, such as intranasal or intravenous abuse. The present disclosure also relates to processes of preparing the dosage form. Such soft chew dosage forms have hardness less than 2 kilopond, preferably less than 1 kilopond, more preferably no measurable hardness when measured with tablet hardness tester and friability less than 1%, preferably less than 0.5%, more preferably less than 0.1% for 100 rotations (per USP); 200 rotations or 300 rotations.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: There are manufactured an enteric capsule comprising: a seamless capsule consisting of a capsule fill and a shell layer; and an enteric coating layer on the shell layer, the enteric coating layer comprising one selected from a methacrylic acid-based polymer, polyvinyl acetate phthalate, organic acid ester of hydroxypropylmethylcellulose, carboxymethylethylcellulose, and cellulose acetate phthalate; and an enteric seamless capsule further comprising a subcoating layer between the shell layer of the seamless capsule and the enteric coating layer, the subcoating layer consisting of hydroxypropylcellulose and the like. The enteric seamless capsule has acid resistance and also enables controlled dissolution for each application site in the body.

Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.

Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.

Abstract: A new method of targeted drug administration to wounds (surgical or traumatic), intrasite (IS), offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing IS medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large IS doses increase risk of toxicity from impurities allowed in drugs given by other routes. Methods are presented for ultrapurification, particularly of endotoxins. Methods are presented for sterile delivery to the wound, to prevent aerosolization, and to homogenize application. Pharmacodynamic parameters make certain drugs advantageous as IS agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an IS medication.

Abstract: A new method of targeted drug administration to wounds (surgical or traumatic), intrasite (IS), offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing IS medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large IS doses increase risk of toxicity from impurities allowed in drugs given by other routes. Methods are presented for ultrapurification, particularly of endotoxins. Methods are presented for sterile delivery to the wound, to prevent aerosolization, and to homogenize application. Pharmacodynamic parameters make certain drugs advantageous as IS agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an IS medication.

Abstract: A non-ingestible transdermal sports tape has an occlusive nonwoven pre-cut tape and night recovery therapy formulation, or a focus therapy formulation or a pre-workout therapy formulation. The occlusive nonwoven pre-cut tape includes a dosage amount pad positioned on one side of the occlusive nonwoven precut tape, an adhesive seal material disposed on a surface of the occlusive non-woven pre-cut tape, a liner material covering the dosage amount pad and the adhesive seal material. The adhesive seal material is configured to adhere to epidermis of an animal body preventing evaporation of water from epidermis while providing a removeable seal. Ingredients of the therapy formulations include non-fermented panax ginseng content, schizandra vitamin B6, vitamin B12, and provides a transdermal absorption from one to eight hours per animal body.

Abstract: The present invention provides a transdermal absorption preparation in which a drug-containing adhesive layer is formed on a support, the aforementioned adhesive layer contains at least a thermoplastic elastomer and a higher fatty acid ester, and a content of a tackifier is not more than 10 wt %, which is superior in drug solubility and releasability, as well as adhesiveness to the skin and low irritation to the skin.

Abstract: The present invention provides a patch comprising a backing and an adhesive layer laminated on one side of the backing, wherein the adhesive layer comprises asenapine or a pharmaceutically acceptable salt thereof, an adhesive base and a low molecular weight amine.

Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C?O)-alkyl, —(C?O)-aryl, —(C?O)-alkyl-aryl, —(C?O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, —SO2CH3, —(C?O)—CH3 or —(C?O)—NH2.

Abstract: Provided is a use of dihydroxyacetone in the preparation of a medicament, the medicament being used for treating a cancer.

Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.

Abstract: A method for the treatment of chronic pain and nutritional replacement is provided. In some implementations, the method consisting of parenteral administration to a patient of ketamine bolus in a dosage amount effective to treat pain followed by a parenteral administration to the patient of a composition comprising an effective amount ketamine, Vitamin C, Vitamin B6, and Vitamin D.

Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

Abstract: This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.

Abstract: The disclosure generally relates to pharmaceutical compositions including a benzhydrylsulfinylacetamide antidepressant and an amount of sodium chloride effective to increase a mean arterial blood pressure of a subject and methods for ameliorating symptoms of dementia including forms of dementia diagnosed as Alzheimer's disease and side-effects associated with the administration of cognition effecting pharmaceuticals.

Abstract: It is to provide a disinfectant liquid which enables easy identification of the application sites in preoperative skin disinfection and the like, where the liquid is obtained by coloring an aqueous solution of olanexidine gluconate which is a colorless and transparent liquid. A disinfectant liquid comprises olanexidine gluconate, a coloring agent such as Sunset Yellow FCF, an alkyl dimethylamine oxide such as lauryl dimethylamine oxide, and optionally one or more surfactants other than alkyl dimethylamine oxide such as polyoxyethylene alkyl ether including lauromacrogol and polyoxyethylene polyoxypropylene alkyl ether including polyoxyethylene(20) polyoxypropylene(4) cetyl ether. The disinfectant liquid enables easy identification of the application sites in preoperative skin disinfection and the like.

Abstract: Disclosed is a pharmaceutical composition including naftazone or one of its pharmaceutically acceptable salts, for its use for the pulsatile release of naftazone or one of its pharmaceutically acceptable salts, wherein: a first pulse of naftazone or one of its pharmaceutically acceptable salts is released substantially immediately upon oral administration of the pharmaceutical composition; and at least one additional pulse of naftazone or one of its pharmaceutically acceptable salts is released at about 3 hours to about 8 hours following the oral administration.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present invention relates to methods for treating microbial infections on the surfaces of an implant or other surfaces near an implant in a patient. In particular, the methods are useful for treating biofilm infections. The methods include the use of minimally invasive techniques, including the use of ultra sound for facilitating the detection of biofilm infections on the implant or other surface of a patient and destroying the infection by administering an anthocyanin or an anthocyanidin or metabolite thereof. In particular, the administration of protocatechuic acid (PCA) or 2,4,6 trihydroxybenzaldehyde (2,4,6 THBA) for the treatment of an infected implant or other surface of a patient is described herein.

Abstract: The invention relates to a method for producing an extract containing hydroxycinnamic acids, characterised in that the method uses one or more vegetable waste products from the production of vegetable food products as a raw material, and comprising the following steps: a) selecting at least one waste product from at least one specific vegetable; b) extracting the hydroxycinnamic acids present in the waste product; c) separating the main liquid phase containing the extracted compounds from the solids; d) clarifying the liquid phase produced in step c); and e) concentrating the clarified liquid phase. The invention also relates to the extract produced via this production method, and the formulations containing this extract.

Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.

Abstract: The disclosure is related to vancomycin resistance and, in particular, to compositions comprising vancomycin for use in inhibiting growth of a vancomycin-resistant microorganism or for use in treating a subject infected with a vancomycin-resistant pathogen. In one aspect, the disclosure provides a composition comprising vancomycin and d-alanine. The disclosure also provides means and methods for treating a subject infected with a vancomycin-resistant microorganism. The disclosure further provides bacteria with a functionally deactivated gene in the vancomycin-resistance cluster.

Abstract: The invention relates to a composition for induction of activity of a nuclear receptor PPARy in a subject in need thereof, which comprises at least one of benzoate or a synergistic combination of benzoate and phenylacetate in association with a pharmaceutical carrier.

Abstract: Products and methods for treating cancer in a human patient comprising administering to the patient therapeutically effective amount of a first pharmaceutically active agent, wherein the first pharmaceutically active agent is one of an isothiocyanatostilbene and a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or a combination thereof.

Abstract: The present invention provides a pharmaceutical composition for oral administration, comprising (a) 4 to 40% by weight of a taxane, (b) 10 to 30% by weight of a medium chain triglyceride, (c) 30 to 70% by weight of monooleoyl glycerol, (d) 5 to 30% by weight of a surfactant, and (e) 10 to 30% by weight of polyoxyl glyceryl fatty acid ester and a process for preparing the same.

Abstract: The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.

Abstract: A cannabinoid formulation for transmucosal delivery includes a first excipient comprising shea butter containing at least 40% oleic acid, at least 20% steraic acid, at least 3% linoleic acid, and at least 2% palmitic acid, a second excipient comprising soy lecithin and a third excipient that is a glycolipid precursor. In one embodiment, the glycolipids precursor is a bioadhesive polysaccharide composed of randomly distributed ?-(1?4)-linked D-glucosamine and N-acetyl-D-glucosamine to improve mucosal and cellular permeability. Preferably the polysaccharide is derived from naturally occurring chitosan. In one embodiment, the polysaccharide is naturally occurring chitosan having a concentration of between 1-20 mg/ml in the formulation. In an alternate embodiment, the polysaccharide is trimethylchitosan having a concentration of between 1-20 mg/ml in the formulation.

Abstract: Methods using cannabinoids and/or molecular similars for modulating, waking-up and/or disabling cellular functions involved in causing disease are provided for reinvigorating metabolism, including human metabolism. As humans age stresses they encounter cause their cells to respond opportunistically to counter each stress. Each of these responses involves at least minor shifts or compromises in metabolism. As these metabolic compromises multiply, metabolism continues to deviate from its optimum. Several lipophilic compounds are active in membranes of cells, including the plasma membrane, nuclear membrane, endoplasmic reticulum membrane and mitochondrial membrane. These lipophilic compounds, act with cannabinoid receptors to affect virtually all cell functions.

Abstract: Provided are: a composition having an excellent anti-norovirus effect; use of a theaflavin compound for the preparation of the composition; and a method for preventing infection with a norovirus using a theaflavin compound. A theaflavin compound is used as an active ingredient for preventing infection with a norovirus. The theaflavin compound is preferably used together with an alcohol. The theaflavin compound is preferably one or more members selected from the group consisting of theaflavin, theaflavin-3-O-gallate, theaflavin-3?-O-gallate and theaflavin-3,3?-O-digallate that are derived from tea components.

Abstract: A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed.

Abstract: The present invention provides an application of a dimethylamino micheliolide for preparing a pharmaceutical product for treating pulmonary fibrosis.

Abstract: The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of the squamous epithelium of a target tissue by reestablishing SPINK7 checkpoint control in the esophageal epithelium, and related compositions and methods.

Abstract: Provided is a composition for use in treating a skin condition, the composition comprising: (a) a first component comprising a substituted or unsubstituted diindolylmethane compound; and (b) a second component comprising a substituted or unsubstituted retinoid compound.